Razoxane
CAS No. 21416-67-1
Razoxane( 4,4'-propylenebis(piperazine-2,6-dione) )
Catalog No. M27828 CAS No. 21416-67-1
Razoxane is used as an antimitotic agent with immunosuppressive properties.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 93 | In Stock |
|
| 5MG | 85 | In Stock |
|
| 10MG | 136 | In Stock |
|
| 25MG | 255 | In Stock |
|
| 50MG | 398 | In Stock |
|
| 100MG | 616 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRazoxane
-
NoteResearch use only, not for human use.
-
Brief DescriptionRazoxane is used as an antimitotic agent with immunosuppressive properties.
-
DescriptionRazoxane is used as an antimitotic agent with immunosuppressive properties.(In Vivo):This tumor model is characterized by osteoid formation and spontaneous metastasization to lungs, kidneys and lymph nodes. Razoxane given intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation (30 mg/kg or 10 mg/kg per day) resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor. Early treatment with razoxane (30 mg/kg i.p. from day -2 to +14) showed a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation). Whereas 59.9 per cent of the total sectional area of the lungs in the control animals was covered by osteosarcoma metastases, only 3.4 per cent and 26.1 per cent respectively was affected in the early and late razoxane treatment groups. Toxic side-effects of these treatment schedules were reversible diffuse alopecia, but no retardation of body weight gain.
-
In VitroRazoxane (30 mg/kg; i.p.) exhibits antimetastatic effects in a rat osteosarcoma model.
-
In VivoEarly treatment with Razoxane (30 mg/kg i.p. from day -2 to +14) shows a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation). Animal Model:Sprague-Dawley ratsDosage:30 mg/kg or 10 mg/kg per day Administration:Intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation Result:Resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor.
-
Synonyms4,4'-propylenebis(piperazine-2,6-dione)
-
PathwayCell Cycle/DNA Damage
-
TargetTopoisomerase
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number21416-67-1
-
Formula Weight268.273
-
Molecular FormulaC11H16N4O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC(CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Tubulin inhibitor 35
Tubulin inhibitor 35 (Tubulin IN 35) is a potent dual inhibitor of topoisomerase I and microtubule protein polymerization with antitumor activity, inhibits migration and invasion of MGC-803 and RKO cell lines, interrupts the cell cycle and induces apoptosis.
-
Rubitecan
Rubitecan is a DNA topoisomerase I inhibitor.?It inhibits DNA topoisomerase I and increases the fraction of supercoiled DNA in a cell-free assay in a concentration-dependent manner.Rubitecan is a semisynthetic agent related to camptothecin with potent antitumor and antiviral properties.
-
Datopotamab deruxtec...
Datopotamab deruxtecan (DS-1062) is a trophoblast cell surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC) with antitumor activity.
Cart
sales@molnova.com